U.S. Medicare plans to cover Biogen Alzheimer’s drug only for trial patients By Reuters

U.S. Medicare plans to cover Biogen Alzheimer's drug only for trial patients By Reuters
U.S. Medicare plans to cover Biogen Alzheimer's drug only for trial patients © Reuters. FILE PHOTO: A sign marks a Biogen facility in Boston, U.S., March 9, 2020. REUTERS/Brian Snyder

By Deena Beasley and Leroy Leo

(Reuters) -The U.S. government Medicare program on Tuesday said it plans to cover Alzheimer’s treatments including Biogen Inc (NASDAQ:)’s Aduhelm but will require patients to be enrolled in a clinical trial, limiting access to the treatment more than many expected.

Biogen shares were down 7.3% at $224 in extended trading on Tuesday. Shares of Biogen’s Japanese partner Eisai Co (OTC:) Ltd slid 2.6% in Tokyo.

The decision from the U.S. Centers for Medicare and Medicaid Services (CMS), the health agency that runs Medicare, could change as it seeks comment from companies and patients. A final decision is due on April 11.

The final CMS coverage terms are expected to…

Continue reading

Leave a Reply

Your email address will not be published. Required fields are marked *